Navarro W H
Division of Hematology/Oncology, University of California, San Francisco, CA 94143-0324, USA.
Bone Marrow Transplant. 2003 Jun;31(11):961-6. doi: 10.1038/sj.bmt.1704052.
Obesity is a common and increasing problem affecting the developed world. Chemotherapy pharmacokinetics in the context of obesity demonstrate prolonged elimination time for several agents, but there is no consensus regarding optimal dosing schemes. Retrospective studies suggest differences in toxicity for obese adult patients but these data may be greatly impacted by chemotherapy dose adjustments. Outcome data from several studies have suggested that obese adult patients suffer poorer disease-free survival and overall survival, although this is not a uniform conclusion in all studies. Prospective studies of chemotherapy pharmacokinetics are needed to address the issue of optimal chemotherapy dosing in the obese population.
肥胖是一个影响发达国家且日益普遍的问题。肥胖背景下的化疗药代动力学显示，多种药物的消除时间延长，但关于最佳给药方案尚无共识。回顾性研究表明肥胖成年患者的毒性存在差异，但这些数据可能受到化疗剂量调整的极大影响。多项研究的结果数据表明，肥胖成年患者的无病生存期和总生存期较差，尽管并非所有研究都得出这一一致结论。需要对化疗药代动力学进行前瞻性研究，以解决肥胖人群中最佳化疗剂量的问题。
